LuminaCare Solutions Accepted into WilmerHale’s QuickStart Program
Company Meets Start Up Program’s Selective Criteria
Boston – July 29, 2013 – LumincaCare Solutions, Inc., a healthcare IT start-up focused on developing a personalized evidence-based dosing platform for the rapid selection of treatments for serious bacterial infections, today announced its acceptance into WilmerHale’s QuickStart Program. The program, recognized by the Financial Times in its 2012 US Innovative Lawyers special report, enables WilmerHale to structure alternative fee arrangements that fit the unique circumstances of emerging companies. Boston-based LuminaCare Solutions meets the program’s strict criteria and will obtain legal counsel from WilmerHale as it continues to grow and succeed.
LuminaCare Solutions provides personalized treatments for infections caused by resistant bacteria with its a patent-pending software platform that rapidly identifies patients at high risk for readmission and increased treatment costs. By utilizing a combination of proprietary analytics and clinical, diagnostic, drug and patient information, LuminiaCare Solutions enables physicians to treat patients with the right drug, dose and treatment duration quickly and accurately to significantly decrease the time to appropriate antibiotic treatment.
“We are thrilled to be accepted into WilmerHale’s QuickStart Program,” said David Howe, CEO and co-founder of LuminaCare Solutions. “With our unique product offering and WilmerHale’s expert legal counsel, LuminaCare Solutions is confident in proceeding with our rapid growth strategy over the next several months.”
“LuminaCare Solutions is a great fit for WilmerHale’s QuickStart Program,” said Ed Pease, Partner at WilmerHale. “The company’s short and long term goals are incredibly promising and we are excited that our Emerging Company Practice will contribute to LuminaCare Solutions’ future success.”
WilmerHale will guide LuminaCare Solutions as it continues to grow and develop strategic alliances with hospitals and health care point-of-care diagnostic companies. These strategic partnerships will be crucial to the development LuminaCare Solutions’ first product for helping patients with drug-resistant bacterial infections.
About LuminaCare Solutions, Inc.
Headquartered in Boston, LuminaCare Solutions provides personalized treatments for infections caused by resistant bacteria with its a patent-pending software platform that rapidly identifies patients at high risk for readmission and increased treatment costs. The platform utilizes a patient database, patient electronic health record information, bacterial diagnostic testing information, quantitative mathematical models for drug behavior and bacteria response, clinical models and data analytics to significantly decrease the time to appropriate antibiotic treatment. For more information visit: www.LuminaCareSolutions.com.
Stephen R. Chiricosta
LuminaCare Solutions, Inc. Stephen@luminacaresolutions.com